US 12,410,183 B2
Sars-cov2 main protease inhibitors
Stephen E. Ammann, Foster City, CA (US); Xinpei Cai, San Mateo, CA (US); Eda Y. Canales, San Mateo, CA (US); Weng K. Chang, San Lorenzo, CA (US); Gregory F. Chin, San Francisco, CA (US); Henok H. Kinfe, Foster City, CA (US); Scott E. Lazerwith, San Francisco, CA (US); Jessica L McKinley, Foster City, CA (US); Michael R. Mish, Foster City, CA (US); Devan Naduthambi, San Bruno, CA (US); Jason K. Perry, San Francisco, CA (US); Kevin X Rodriguez, San Mateo, CA (US); Scott D. Schroeder, Union City, CA (US); Christopher J. Swank, San Mateo, CA (US); and Joshua J. Van Veldhuizen, Seattle, WA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Jun. 14, 2024, as Appl. No. 18/743,475.
Application 18/743,475 is a continuation of application No. 18/376,159, filed on Oct. 3, 2023, granted, now 12,091,420.
Application 18/376,159 is a continuation of application No. 18/365,919, filed on Aug. 4, 2023.
Claims priority of provisional application 63/508,350, filed on Jun. 15, 2023.
Claims priority of provisional application 63/486,156, filed on Feb. 21, 2023.
Claims priority of provisional application 63/482,750, filed on Feb. 1, 2023.
Claims priority of provisional application 63/476,359, filed on Dec. 20, 2022.
Claims priority of provisional application 63/375,522, filed on Sep. 13, 2022.
Claims priority of provisional application 63/370,629, filed on Aug. 5, 2022.
Prior Publication US 2025/0042915 A1, Feb. 6, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 495/04 (2006.01); A61P 31/14 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 491/107 (2006.01); C07D 491/113 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 495/04 (2013.01) [A61P 31/14 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 491/107 (2013.01); C07D 491/113 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01)] 25 Claims
 
1. A method of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human a compound selected from

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.